Hansoh Signs $456 Million Agreement for siRNA Products from OliX Pharma
October 12, 2021 at 05:42 AM EDT
Hansoh Pharma of Shanghai announced a $456 million agreement to develop siRNA products in Greater China from South Korea 's OliX Pharma. The two companies will collaborate using OliX's GalNAc-asiRNA platform for various liver-based targets that are implicated in cardiovascular, metabolic and other indications. Hansoh will make an upfront payment of $6.5 million and up to $450 million in milestones. OliX will continue to hold rights to the products in the rest of the world. More details.... Stock Symbols: (HK: 3692) (KOSDAQ: 226950) Share this with colleagues: // //
